Modality
Bispecific Ab
MOA
VEGFi
Target
PARP
Pathway
Sphingolipid
IPFNMOSDAsthma
Development Pipeline
Preclinical
~Dec 2011
→ ~Mar 2013
Phase 1
~Jun 2013
→ ~Sep 2014
Phase 2
~Dec 2014
→ ~Mar 2016
Phase 3
~Jun 2016
→ ~Sep 2017
NDA/BLA
Dec 2017
→ Jul 2030
NDA/BLACurrent
NCT08537250
2,884 pts·Asthma
2021-12→2030-07·Active
NCT04426306
2,526 pts·IPF
2017-12→TBD·Active
5,410 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-084.3y awayPh3 Readout· Asthma
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Active
NDA/BLA
Active
Catalysts
Ph3 Readout
2030-07-08 · 4.3y away
Asthma
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08537250 | NDA/BLA | Asthma | Active | 2884 | PASI75 |
| NCT04426306 | NDA/BLA | IPF | Active | 2526 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |